Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies

作者：Borras Blasco Joaquin^*; Navarro Ruiz Andres

来源：Expert Review of Pharmacoeconomics and Outcomes Research: Informing Decision-Making in the Delivery of Cost-Effective Healthcare , 2015, 15(1): 71-79.

DOI：10.1586/14737167.2015.967219

• adalimumab
• anti-TNF
• cost-effectiveness
• dose modification
• etanercept
• infliximab
• real-world data
• rheumatoid arthritis

Anti-TNF drugs indicated for the treatment of moderate-to-severe active rheumatoid arthritis (RA) presents similar efficacy, safety and potential toxicity profiles, with more than 10 years' treatment experience. Several pharmacoeconomic evaluations had demonstrated their favorable cost-effectiveness profile in RA patients, based on pivotal clinical studies data from different countries and perspectives. However, in clinical practice, individual profiles of patients and drugs leads to dose modifications that may be associated with substantial cost deviations. Here, we further discuss the effect of dose titration of these biological drugs in clinical practice over their RA cost-effectiveness profiles.

• 出版日期2015-2